Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04667442 · ClinicalTrials.gov registry record
Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects
A clinical trial, sponsored by Nanomix.
- Completed
- Registry status
- 137
- Enrollment target
NCT04667442: Completed study, sponsored by Nanomix.
NCT04667442 is a clinical trial that has completed, run by Nanomix. The registered enrollment target is 137 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04667442 has completed, sponsored by Nanomix.
- COMPLETED
- Registry status
- 137 participants
- Enrollment target
Study Summary
Prospective samples will be collected to evaluate the agreement between a EUA RT-PCR test as the comparator method against the Nanomix eLab® system.
Primary Outcome
An analysis of the result from subjects who have been or will be tested by EUA RT-PCR will be performed to establish the sensitivity by positive percent agreement (PPA) and the specificity by negative percent agreement (NPA) of the Nanomix eLab® COVID-19 Rapid Antigen Panel and a confirmatory EUA RT-PCR method.
Interventions
- DIAGNOSTIC_TEST Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2021-12-14 |
What the finished NCT04667442 record still lists
NCT04667442 is an observational study that tracks outcomes without assigning an intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional) is the first listed.
NCT04667442 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04667442 about?
NCT04667442 is a clinical study titled "Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects". Prospective samples will be collected to evaluate the agreement between a EUA RT-PCR test as the comparator method against the Nanomix eLab® system.
What is the current status of trial NCT04667442?
This trial is currently completed. The enrollment target is 137 participants. The study started on 2020-12-01. Estimated completion is 2021-12-14.
What interventions are being tested in trial NCT04667442?
The interventions under investigation include: Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04667442?
This trial is sponsored by Nanomix, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI